Some synthetic PPAR ligands have been widely used in the treatment of dyslipidemia (e.g., fibrates–PPARα activators) and diabetes mellitus (e.g., thiazolidinediones–PPARγ agonists) [30,31]. The gene discussed is PPARA; the disease is diabetes mellitus.